| Description |
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].
|
| Related Catalog |
|
| In Vitro |
Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1]. Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1]. Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902)[1]. Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1].
|
| In Vivo |
Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2]. Animal Model: MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] Dosage: 5 mg/kg Administration: IP, twice a week, 3weeks Result: Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group.
|
| References |
[1]. Huang Z, et al. Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events. Front Immunol. 2022 Jun 27;13:924542. [2]. Yunlong Shan, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 2581-2581.
|
